Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review explored treatment options for alopecia areata in the military health care system, evaluating the pathogenesis and impact of the condition as well as the efficacy and safety of FDA-approved JAK inhibitors, baricitinib and ritlecitinib.

This study examined phase 3 clinical trial data and found that baricitinib improves hair regrowth in adults with alopecia areata and significant scalp hair loss, with the response varying based on the severity of hair loss at the start of treatment.

This study demonstrated that the Alopecia Areata Disease Activity Index (ALADIN), a new biomarker, strongly correlates with treatment response in patients using JAK inhibitors for alopecia areata.

This research discusses the parallel clinical development of ritlecitinib, an oral Janus kinase 3/tyrosine kinase inhibitor, for treating conditions such as alopecia areata, vitiligo, ulcerative colitis, Crohn's disease, and rheumatoid arthritis. Results are not reported in the abstract.

This study observed that retinoic acid biosynthesis and signaling in hair follicles have a spatial and temporal regulation linked to distinct stages of the hair cycle in mice.

This study found that while 51.3% of severe alopecia areata patients achieved significant hair regrowth with intravenous methylprednisolone, oral Janus kinase inhibitors may benefit those who do not respond to this treatment.

In this study, researchers developed a dissolvable microneedle patch containing baricitinib for alopecia areata treatment, reporting significantly higher hair growth in mouse models compared to controls, suggesting its potential as an effective, pain-free topical therapy.

In this study using a rabbit model, higher incidences of intraoperative floppy iris syndrome were observed in animals given the α-blocker tamsulosin, suggesting a potential association with increased iris billowing during eye surgery.

This case report highlights the successful treatment of a 37-year-old male with steroid-resistant beard alopecia areata using baricitinib, a JAK-1/2 inhibitor, over 9 months, resulting in reduced hair loss and improved hair density.

In this study, researchers administered injectable platelet-rich fibrin (i-PRF) to 30 patients with androgenetic alopecia, finding an 80% response rate after 6 months, with improved hair density and reduced scalp symptoms, while reporting minimal adverse reactions.

This study in Arabidopsis thaliana found that exposure to volatile compounds from Penicillium aurantiogriseum promotes root hair growth through signaling involving RALF22, ethylene, auxin, and photosynthesis, and that RALF22 plays a crucial role in the plants' response to these compounds.

This study supports the use of a national registry as an effective tool for documenting epidemiological data, disease progression, treatment responses, and quality of life impacts in patients with alopecia areata.

This article highlights disparities in the prevalence of alopecia areata among people with skin of color and suggests this information could help dermatologic providers address challenges in treating this population.

This project by the International Society of Hair Restoration Surgery reviews best practices in hair restoration surgery and reports no new research findings.

This report observed that a patient with alopecia areata, resistant to ritlecitinib, experienced significant recovery after 24 weeks of treatment with upadacitinib, highlighting its potential in treating ritlecitinib-resistant cases and suggesting personalized treatment strategies in managing alopecia areata.

This abstract reflects on the author's journey in hair restoration surgery since 1986, but it presents no new research findings.

This study found that the systemic immune-inflammation index (SII) can be used as a cost-effective marker to assess the severity and treatment response in patients with alopecia areata.

This study described a case where both alopecia universalis and Crohn's ileitis in a 23-year-old man showed remarkable improvement with the JAK1 inhibitor upadacitinib, highlighting its potential as a treatment for patients with concurrent conditions.

In this report, NICE has approved ritlecitinib, an oral kinase inhibitor, as the first recommended treatment for severe alopecia areata in individuals aged 12 and older.

This report announces that the International Society of Hair Restoration Surgery received Accreditation with Commendation.

In this study, baricitinib was evaluated for its effectiveness in promoting concurrent regrowth of scalp hair, eyebrows, and eyelashes in patients with severe alopecia areata, showing clinically meaningful responses compared to placebo.

This study found that baricitinib, when administered consistently over three years, maintained its efficacy in patients with severe alopecia areata who responded by Week 52 with notable hair regrowth, indicated by a SALT score of ≤20.

ASLAN004 was safe and well-tolerated, supporting further development for treating certain diseases.

This study found that patients with alopecia areata had significantly higher serum IL-1R1 levels, IL-1R1 gene expression, and hsa-miR-19b-3p levels compared to healthy controls, suggesting these could serve as diagnostic and prognostic markers for the disease's severity.

The study found that IPI-926 was well tolerated up to 160 mg once daily for 28-day cycles and showed activity as a single-agent treatment in Hedgehog pathway inhibitor-naïve patients with basal cell carcinoma.

In this study, researchers found that activating RORA in hair follicle stem cells reduced the expression of cytoskeleton-related genes, affecting cell migration and adhesion, which may aid in understanding hair follicle development and potentially inform alopecia treatments.

This case report details the successful use of oral itraconazole in treating a giant tufted angioma with hair loss that developed during pregnancy, leading to significant symptom relief and hair regrowth after discontinuation of the medication.

This system overview describes the UTokyo Repository's role in storing and providing online access to digital resources from the University of Tokyo, reporting no new empirical findings or research results.

AI can accurately measure hair loss severity in alopecia areata.

In this study, researchers evaluated CS12192, a selective JAK3 inhibitor, in an alopecia areata mouse model and found it reversed hair growth inhibition comparably to baricitinib, with better safety and similar immune-modulating mechanisms.